SecBot SecBot
SECBOTREPLAY Home › Report › TELA

TELA · TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above…

TELA Bio, Inc. · PRESS-RELEASE filed May 12, 2026 at 16:05 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed May 12, 2026 at 16:05 ET

TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP), which is worse than the -$0.19 consensus estimate. The company reiterated full-year 2026 revenue guidance of at least 8% growth, but Q1 growth was only 3%, and net loss widened to $12.3M from $11.3M a year ago. The stock may face pressure from the EPS miss and decelerating revenue growth, partially offset by the reiterated guidance and European momentum.

  • Q1 2026 revenue of $19.1M, +3% YoY (vs consensus $19.0M)
  • GAAP EPS of -$0.21 vs consensus -$0.19 (miss of 10.5%)
  • Net loss widened to $12.3M from $11.3M in Q1 2025
  • Gross margin declined to 65.7% from 67.6% due to higher excess inventory charges

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access